Boltz vs IBM
Side-by-side comparison of AI visibility scores, market position, and capabilities
Open-source AI for biomolecular structure prediction. $28M seed from a16z. Pfizer collaboration. Boltz-2 rivals physics methods at 1000x speed. MIT spinout.
About
Boltz was founded as a spinout from MIT with a mission to democratize access to AI-driven biomolecular structure prediction. The company was inspired by the transformative impact of AlphaFold on structural biology and sought to build the next generation of prediction systems that could go beyond protein structure to model the full complexity of biomolecular interactions, including protein-ligand binding, RNA folding, and multi-chain assemblies. By releasing its models as open source, Boltz made frontier-grade structural biology tools available to any researcher with a computer.\n\nBoltz-2, the company's latest model, rivals physics-based molecular dynamics simulations in accuracy while operating at approximately 1,000 times the speed, compressing computational experiments that once required weeks into hours or minutes. This performance profile makes Boltz-2 practical for drug discovery workflows where structural predictions must be generated across millions of candidate molecules. Boltz entered a collaboration with Pfizer, one of the world's largest pharmaceutical companies, to apply its models to drug discovery programs — a validation of both the technology's accuracy and its readiness for industrial-scale deployment.\n\nBoltz raised a $28 million seed round led by Andreessen Horowitz's bio fund, reflecting a16z's conviction that open-source biomolecular AI represents a foundational layer of the next generation of drug discovery infrastructure. The open-source strategy gives Boltz broad academic adoption and a rich pipeline of community feedback that accelerates model improvement. Its MIT lineage, Pfizer partnership, and a16z backing position Boltz as a leading independent AI platform in the computational biology space.
Armonk NY hybrid cloud and enterprise AI (NYSE: IBM) at $62.8B revenue; $6B+ generative AI bookings, record $12.7B free cash flow 2024, DataStax acquisition for watsonx vector database competing with Microsoft Azure for enterprise AI.
About
International Business Machines Corporation (IBM) is an Armonk, New York-based global technology and consulting company — publicly traded on the New York Stock Exchange (NYSE: IBM) as an S&P 500 component — providing hybrid cloud infrastructure, artificial intelligence software, and enterprise IT consulting through approximately 270,300 employees in 170 countries with $62.8 billion in annual revenue. Founded on June 16, 1911, as Computing-Tabulating-Recording Company through a merger orchestrated by financier Charles Ranlett Flint, renamed IBM in 1924 under Thomas Watson Sr., IBM has undergone multiple strategic transformations over its 110+ year history: building the System/360 mainframe platform (1964), launching the IBM PC (1981), selling the PC division to Lenovo (2005, $1.75B), and completing the $34 billion Red Hat acquisition (2019) that repositioned IBM as a hybrid cloud platform company. CEO Arvind Krishna (appointed April 2020) has focused IBM's strategy on three areas: hybrid cloud (powered by Red Hat OpenShift, the enterprise Kubernetes platform), AI (the watsonx platform for enterprise AI model development and deployment), and enterprise consulting. Under Krishna, IBM recorded $12.7 billion in free cash flow in 2024 (a company record), surpassed $6 billion in generative AI bookings since June 2023, and saw the stock price double — trading at all-time highs through 2024-2025. IBM announced the DataStax acquisition in 2025 to deepen watsonx's data layer with AstraDB (vector database for AI applications), DataStax Enterprise (Apache Cassandra), and Langflow (low-code AI agent development).
AI Visibility Head-to-Head
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.